Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

LGND 52.32 +0.19 (0.36%)
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Why Ligand Pharmaceuticals Inc. Shares Popped
What: Shares of Ligand Pharmaceuticals (NASDAQ: LGND ) , a biotechnology company that develops and acquires royalty rights to pharmaceutical products, gained as much as 15% after the company reported better than expected fourth-quarter results and ...
Related articles »  
Lemelson Increases Ligand Pharmaceuticals Inc. (LGND) Short
4, 2014 /PRNewswire/ - Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and updated with new information its June 16 ...
Update: Lemelson Capital Further Increases Short Stake In Ligand ...  Seeking Alpha (registration)
Related articles »  
Ligand Pharmaceuticals Inc. Stock Upgraded (LGND)
This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, LIGAND PHARMACEUTICAL INC's return on equity exceeds that of both the industry average and the S&P 500.
Related articles »  
Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transactions.
Related articles »  
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga's #PreMarket Prep to talk about why he thinks ...
Related articles »  
Ligand Pharmaceuticals Inc. (LGND), Inovio Pharmaceuticals Inc (INO), & Tejon ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Inovio Pharmaceuticals Inc (NASDAQ:INO) are two stocks from the pharma space that have recently seen insiders buying shares in large quantities.
Related articles »  
Lemeson Ups Ligand Pharmaceuticals Inc. (LGND) Short
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and appended with additional concerns its initial June 16, 2014 research ...
Ligand Pharmaceuticals: Appendix  Seeking Alpha
Related articles »  
Ligand Pharmaceuticals Inc. (LGND)'s Coverage Initiated By B. Patrick
James noted that the biotechnology company has more than 90 fully funded programs with royalty generating products. According to the analyst, Ligand Pharmaceuticals Inc. (NASDAQ:LGND) generates its current cash flows from royalties from the sales of ...
Related articles »  
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To ...
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported on Tuesday it expects its fiscal 2015 earnings per share to be in a range of $2.14 to $2.18, falling short of the consensus estimate of $2.42.
Ligand Pharmaceuticals Inc. (LGND) Updates FY15 Earnings Guidance  Ticker Report
Related articles »